NRC vs DBVT

National Research Corporation (NRC) offers the better valuation at 37.

6x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, National Research Corporation (NRC) delivered a total return of -52.

0%, compared to -66. 9% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: NRC returned +91. 8% versus DBVT's -88. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), National Research Corporation (NRC) is the lower-risk stock at 0.

80β versus DBV Technologies S. A. 's 1. 11β — meaning DBVT is approximately 39% more volatile than NRC relative to the S&P 500. On balance sheet safety, DBV Technologies S. A. (DBVT) carries a lower debt/equity ratio of 13% versus 6% for National Research Corporation — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: National Research Corporation grew EPS -50.

0% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

National Research Corporation (NRC) is the more profitable company, earning 8.

4% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 8. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NRC leads at 16. 4% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — NRC leads at 56. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, NRC (2.

5% yield) pays a dividend. DBVT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, National Research Corporation (NRC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

80), 2. 5% yield). Both have compounded well over 10 years (NRC: +91. 8%, DBVT: -88. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

NRC pays a dividend while DBVT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.